MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Search

Lyell Immunopharma Inc

Затворен

0.46

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.45

Максимум

0.48

Ключови измерители

By Trading Economics

Приходи

-147M

-192M

Продажби

-23K

11K

EPS

-0.172

Марж на печалбата

-1,744,863.636

Служители

300

EBITDA

-12M

-58M

Препоръки

By TipRanks

Препоръки

Продай

12-месечна прогноза

+117.39% upside

Дивиденти

By Dow Jones

Следващи печалби

5.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-57M

159M

Предишно отваряне

0.46

Предишно затваряне

0.46

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Lyell Immunopharma Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.04.2025 г., 22:38 ч. UTC

Горещи акции

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

5.04.2025 г., 09:30 ч. UTC

Печалби

Elon Musk's Mr. Fix-It Takes Center Stage During a Really Bad Week -- WSJ

5.04.2025 г., 01:00 ч. UTC

Придобивния, сливания и поглъщания

How BlackRock's Larry Fink Won Over Donald Trump -- WSJ

5.04.2025 г., 01:00 ч. UTC

Придобивния, сливания и поглъщания

How BlackRock's Larry Fink Won Over Donald Trump -- WSJ -2-

4.04.2025 г., 21:53 ч. UTC

Пазарно говорене

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

4.04.2025 г., 21:44 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

4.04.2025 г., 21:00 ч. UTC

Топ новини

Americans Were Souring on Trump's Economic Plans Even Before Tariff Bloodbath -- WSJ

4.04.2025 г., 20:52 ч. UTC

Пазарно говорене

Peloton Likely to Escape Tariffs Unscathed -- Market Talk

4.04.2025 г., 20:52 ч. UTC

Топ новини

Trump Can Cut Teacher-Training Programs For Now, Supreme Court Says -- WSJ

4.04.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

4.04.2025 г., 20:48 ч. UTC

Топ новини

The Score: Nike, Apple, Stellantis and More Stocks That Defined the Week -- WSJ

4.04.2025 г., 20:45 ч. UTC

Топ новини

Hiring Defied Expectations in March, With 228,000 New Jobs -- 6th Update

4.04.2025 г., 20:32 ч. UTC

Топ новини

Dow Tumbles 2,000 Points, Bonds Rally After China Retaliates Against Trump Tariffs -- WSJ

4.04.2025 г., 20:21 ч. UTC

Топ новини

China Hits Back at Trump With Sweeping Tariffs on All U.S. Goods -- Update

4.04.2025 г., 20:00 ч. UTC

Топ новини

Republicans March Ahead on Trump's Tax Cuts as Tariffs Kick In -- WSJ

4.04.2025 г., 19:51 ч. UTC

Пазарно говорене

Dollar Recovers While Recession Fears Grip Wall Street -- Market Talk

4.04.2025 г., 19:37 ч. UTC

Топ новини

Trump's Team is Getting the Bond Rally It Wanted. But for the Wrong Reasons. -- WSJ

4.04.2025 г., 19:32 ч. UTC

Пазарно говорене

Oil Selloff Continues as China Responds to U.S. Tariffs -- Market Talk

4.04.2025 г., 19:28 ч. UTC

Топ новини

U.S. Stocks Fall Further After China Retaliates Against Trump Tariffs -- Update

4.04.2025 г., 19:15 ч. UTC

Пазарно говорене

Costco Gold, Membership Fees Could Help Cushion from Tariff Costs -- Market Talk

4.04.2025 г., 19:12 ч. UTC

Топ новини

Powell Warns of Higher Prices, Weaker Growth After Tariff Plan -- 3rd Update

4.04.2025 г., 19:11 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls as Global Selloff Continues -- Market Talk

4.04.2025 г., 19:09 ч. UTC

Пазарно говорене

Mexican Stocks, Peso Tumble as Global Rout Continues -- Market Talk

4.04.2025 г., 19:09 ч. UTC

Топ новини

Trump Grants 75-Day Extension to Reach TikTok Deal -- Second Update

4.04.2025 г., 19:00 ч. UTC

Пазарно говорене

Fed Has Limited Options to Counter Tariffs -- Market Talk

4.04.2025 г., 18:53 ч. UTC

Пазарно говорене

Brace for Trump's Tariff Order to Remain in Place for Extended Period -- Market Talk

4.04.2025 г., 18:51 ч. UTC

Пазарно говорене

Morgan Stanley Analysts Outline Paths to Recession -- Market Talk

4.04.2025 г., 18:44 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

4.04.2025 г., 18:44 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

4.04.2025 г., 18:44 ч. UTC

Пазарно говорене

Tariffs Won't Achieve What Trump Wants, Morgan Stanley Says -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Lyell Immunopharma Inc Прогноза

Ценова цел

By TipRanks

117.39% нагоре

12-месечна прогноза

Среден 1 USD  117.39%

Висок 1 USD

Нисък 1 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Lyell Immunopharma Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Продай

2 ratings

0

Купи

1

Задържане

1

Продай

Техническа оценка

By Trading Central

0.461 / 0.482Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

No Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Lyell Immunopharma Inc

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.